Iovance raises FY 2026 total revenue guidance to $410 million-$420 million

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Iovance Biotherapeutics raised full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million. * The midpoint increase is $55 million, about 15%, implying nearly 60% annual growth in total revenue. * Outlook reflects strong U.S. demand for Amtagvi and Proleukin. * Second-quarter 2026 total product revenue reached a record $99.3 million. * Authorized treatment center network expanded to about 100 centers, targeting at least 110 by year-end 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290700PRIMZONEFULLFEED9835587) on September 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.